A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

• Status: Completed
• Trial end date: 2014-05-01

Summary

The purpose of this study is to compare the efficacy and safety of intravenous iron therapy with oral iron therapy in patients with cancer and chemotherapy induced anaemia.

• Phase: Phase 3

Details

• Lead Sponsor: Pharmacosmos A/S
• Treatments: Ferric Compounds; Hematinics; Iron; Iron isomaltoside 1000